ALEPHYA-EDUCATION
2.9.2024 05:31:33 CEST | Business Wire | Press release
AlephYa Education (“AlephYa” or “Company”), a leading pan-GCC education provider, today announced a majority investment from TA Associates (“TA”), a leading global private equity firm, to support its next phase of growth. As part of the transaction, existing investors Gulf Investment Corporation (“GIC”) and Oman International Development and Investment Company SAOG (“Ominvest”) will retain a meaningful stake in the business, partnering closely with TA. Ashmore Investment Saudi Arabia (“Ashmore”), an investor in AlephYa since 2017, will fully exit its investment in the Company.
Founded in 2017, AlephYa has become a fast-expanding school platform committed to providing high-quality, affordable education to local and expat families across the Middle East. The Company’s network of schools offers a mix of American, British and local curricula designed to empower students with the skills to become future leaders while retaining their national heritage. Today, AlephYa owns and operates 13 schools across Saudi Arabia, UAE and Oman, with a combined enrollment of over 18,500 students.
“Since AlephYa’s founding only seven years ago, the Company has established a strong, diversified platform driven by an impressive track record of M&A and operational excellence. As experienced investors in the education space, we see great potential for AlephYa’s continued expansion, both organically and through strategic acquisitions,” said Dhiraj Poddar, Managing Director at TA. “We are thrilled to partner with the AlephYa team to achieve further scale and bring high-quality, affordable education to more communities across the GCC,” added Vishal Gupta, Director at TA.
“TA shares our commitment to academic excellence, and their investment provides a major opportunity to enhance our educational infrastructure, improve our facilities and increase our impact on new and existing students,” said Shailesh Doshi, CEO and Co-Founder of AlephYa. “We are excited to welcome TA as an investor and look forward to leveraging their deep expertise in scaling companies to reach our full potential,” added Nadeem Masud and Chandra Tiwari, Co-Founders of AlephYa.
“Since investing in the Company in 2017, it has been a privilege to significantly scale AlephYa working alongside Ominvest and GIC during a period of such transformational growth,” commented Ibrahim Assem, Head of Private Equity, MENA at Ashmore Group plc. “We wish AlephYa and its shareholders the best as they solidify its position as one of the largest school groups in the region,” added Kartik Patel, Head of Alternatives at Ashmore Investment Saudi Arabia.
“We believe AlephYa is well-positioned to sustain its rapid growth as the demand for accessible, high-quality education continues to increase across the GCC. This transaction is part of GIC’s strategy to partner with leading global firms and we look forward to the next chapter ahead in partnership with TA,” said Mohammad Al-Fares, Head of Diversified Projects Division at GIC.
“We are pleased to welcome TA as a fellow investor in AlephYa. As knowledgeable investors in the education sector, we are confident TA’s partnership will enable us to enhance AlephYa’s offering and further strengthen its footprint. This investment is aligned with Ominvest’s Purpose Statement of transforming businesses to enrich societies,” commented Badar Al Shanfari, Chief investment Officer (Private Equity) at Ominvest.
PwC Middle East served as financial advisor to TA. Al Tamimi & Company and Goodwin Procter LLP provided legal counsel to TA. Financial terms of the transaction were not disclosed.
About AlephYa Education
Established in 2017, AlephYa is a leading educational group that owns and operates schools across the GCC. AlephYa has a core focus on nurturing global citizens and empowering students with the skills to become future leaders, providing high-quality education that is affordable and accessible to every child. The platform’s approach to education is focused around the five attributes of academic excellence, community, collaboration, heritage and corporate and social responsibility. To learn more, visit www.alephyaeducation.com.
About Ashmore Investment Saudi Arabia
Based in Riyadh, Ashmore Investment Saudi Arabia was founded in 2014 and is part of Ashmore Group plc. Ashmore Group is one of the world's leading investment managers dedicated to Emerging Markets with USD 49.5 billion (as at 30 June 2024) invested for clients across the globe. These include central banks, government and corporate pension funds, institutions and high net worth individuals. Ashmore offers a number of investment themes, including External Debt, Local Currency, Corporate Debt, Blended Debt, Equities, Alternatives, Overlay/Liquidity and Multi-Asset. To learn more, visit www.ashmoregroup.com.
About Gulf Investment Corporation
Gulf Investment Corporation (GIC) is an investment company incorporated in the State of Kuwait on November 15, 1983 as a Gulf Shareholding Company. It is equally owned by the governments of the six-member states of the Gulf Cooperation Council (GCC). GIC was formed to foster economic growth, economic diversification and capital markets development across the GCC region. To learn more, visit www.gic.com.kw.
About Ominvest
Founded in 1983 and listed on the Muscat Securities Exchange, Ominvest is a leading investment company in the region with a track record of consistent profits and dividend payments to shareholders. At Ominvest, we take a global approach to investing and hold a diversified portfolio of investments in markets beyond Oman, including the GCC, Asia and other international growth markets. Our investments are diversified across insurance, banking & finance, private equity, global capital market investments, real estate and technology. www.ominvest.com
About TA
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and business services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has over 150 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. For more information, visit: www.ta.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240901234095/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom